The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency  Sonya Cressman, PhD, Stuart J. Peacock, DPhil, Martin C. Tammemägi, PhD, William K. Evans, MD, Natasha B. Leighl, MD, John R. Goffin, MD, Alain Tremblay, MDCM, Geoffrey Liu, MD, Daria Manos, MD, Paul MacEachern, MD, Rick Bhatia, MD, Serge Puksa, MD, Garth Nicholas, MD, Annette McWilliams, MD, FRCSC, John R. Mayo, MD, John Yee, MD, FRCSC, John C. English, MD, Reka Pataky, MS, Emily McPherson, MA, Sukhinder Atkar-Khattra, BSc, Michael R. Johnston, MD, FRCSC, Heidi Schmidt, MD, Frances A. Shepherd, MD, Kam Soghrati, MD, Kayvan Amjadi, MD, Paul Burrowes, MD, Christian Couture, MD, MSc, Harmanjatinder S. Sekhon, MD, PhD, Kazuhiro Yasufuku, MD, PhD, Glenwood Goss, MD, Diana N. Ionescu, MD, David M. Hwang, MD, Simon Martel, MD, Don D. Sin, MD, Wan C. Tan, MD, Stefan Urbanski, MD, Zhaolin Xu, MD, Ming-Sound Tsao, MD, Stephen Lam, MD  Journal of Thoracic Oncology  Volume 12, Issue 8, Pages 1210-1222 (August 2017) DOI: 10.1016/j.jtho.2017.04.021 Copyright © 2017 Terms and Conditions

Figure 1 Source data from the National Lung Cancer Screening Trial (NLST). Abbreviations: LDCT, low-dose computed tomography; CXR, chest radiography. Journal of Thoracic Oncology 2017 12, 1210-1222DOI: (10.1016/j.jtho.2017.04.021) Copyright © 2017 Terms and Conditions

Figure 2 (A) Decision-analytic model for risk-selected (low-dose computed tomography) LDCT screening versus no screening (assumed to be equivalent to chest radiography screening). The decision tree branches lead to one of three Markov models (high-risk screened model [HRSM], high-risk unscreened model [HRUSM], or low-risk unscreened model [LRUSM]): the HRSM simulates outcomes for individuals with a high risk who are screened with LDCT, the HRUSM simulates outcomes for high-risk individuals who do not receive LDCT-based lung screening, and the LRUSM simulates outcomes and costs for individuals with a low risk who do not receive LDCT-based screening. (B) Markov model health states. Journal of Thoracic Oncology 2017 12, 1210-1222DOI: (10.1016/j.jtho.2017.04.021) Copyright © 2017 Terms and Conditions